Myfortic (Mycophenolic Acid)

Mycophenolic acid, the active moiety of Myfortic, selectively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH). This blockade reduces the synthesis of guanosine nucleotides, which are essential for the proliferation of T and B lymphocytes. By limiting lymphocyte expansion, the drug suppresses the immune response that can attack a transplanted organ.

The dose of Myfortic is individualized by the prescribing clinician based on factors such as the type of transplant, the patient’s renal and hepatic function, concomitant immunosuppressive therapy, and therapeutic drug monitoring results. No fixed regimen is provided here; the prescriber sets the appropriate dosage for each patient.

Myfortic is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should be avoided during pregnancy unless the potential benefit justifies the risk. Limited data are available for breastfeeding, and the drug may be excreted in milk; therefore, nursing mothers should discuss alternatives with their healthcare provider.

To order Myfortic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Myfortic (mycophenolate sodium) and mycophenolate mofetil (CellCept) belong to the same antimetabolite class and share a similar mechanism of IMPDH inhibition. Myfortic is formulated as a delayed‑release tablet, which may improve gastrointestinal tolerability for some patients. Choice between the two often depends on physician preference, patient tolerance, and specific formulary considerations.

Myfortic tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container to protect from moisture and light. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Myfortic is taken orally as a delayed‑release tablet. The tablet should be swallowed whole with water and not crushed, chewed, or split, to preserve the controlled‑release properties. Dosing times are usually spaced evenly throughout the day as directed by the prescriber, often in combination with other immunosuppressants.

Serious risks include opportunistic infections such as cytomegalovirus or Pneumocystis jirovecii pneumonia, severe hematologic abnormalities like profound leukopenia or thrombocytopenia, neurotoxic events such as seizures or posterior reversible encephalopathy syndrome, and an increased long‑term risk of certain malignancies, particularly lymphoproliferative disorders and skin cancers.

Myfortic is contraindicated in patients with known hypersensitivity to mycophenolate sodium or any component of the formulation. It should also be avoided in individuals with severe, uncontrolled infections, active malignancy, or significant bone‑marrow suppression. Pregnant women should not use it unless the potential benefit outweighs the risk, and it is generally not recommended for breastfeeding mothers without specialist advice.